Ortivus AB (publ) interim report for the period January – March 2023

Ortivus initiates customer delivery projects in the Baltics

Highlights January – March 2023

  • Ortivus signs a framework agreement with East of England NHS Collaborative Procurement Hub regarding MobiMed ePR, creating new opportunities in the UK. The agreement means that all UK Ambulance Trusts can call-off electronic patient records – ePR solutions, from all qualified companies. The contract period is 2 years from the start date.
  • Ortivus signs a contract regarding the delivery of MobiMed ePR to the Estonian ambulance fleet. The contract has an order value of approximately 26 MSEK over a period of 5 years with a possible extension for another 5 years. The extension period also has an estimated order value of 26 MSEK.
  • Ortivus signs a framework agreement with Stockholm County Healthcare District (SLSO) regarding MobiMed Life, semi-automatic defibrillators. The customer will call-off units as need arises. The total order value for the entire framework agreement period, which is four years, amounts to a maximum of 2.4 MSEK.
  • Ortivus AB acquires approx. 10% of the company H&E Solutions AB, a Swedish technology company that has developed Evam – an operating system for emergency vehicles.

Significant events after end of the period

  • Ortivus qualifies for the NHS framework agreement covering MobiMed Life, which creates new opportunities in the UK.
  • Ortivus’ product range is further broadened via an asset purchase agreement of the vehicle control system FleetCtrl, which together with Ortivus’ other products form a competitive total solution for the future of healthcare.

January – march 2023

  • Net sales amounted to 28.0 (24.6) MSEK.
  • The gross margin amounted to 48% (47%).
  • EBITDA amounted to 0.2 (2.0) MSEK.
  • Earnings after tax per share before and after dilution amounted to 0.01 (0.04) SEK.
  • Operating cash flow before changes in working capital amounted to 1.5 (2.4) MSEK.
Jan-Mar 2023 Jan-Mar 2022 Jan-Dec 2022
Net sales (MSEK) 28.0 24.6 104.5
Gross margin (%) 48% 47% 47%
Operating profit (MSEK) 0.5 2.0 5.8
Operating margin (%) 2% 8% 6%
EBITDA (MSEK) 1.5 2.9 10.2

Contacts

For further information, please contact

Reidar Gårdebäck, CEO

Telefon +46 8 446 45 00

About Ortivus

Ortivus develops and commercialises MobiMed, e-health and medical technology solutions for a safer and more efficient healthcare. The company was founded in 1985 and is today a leading provider of mobile digital solutions for prehospital care, worldwide. Ortivus' innovations are based on in-depth expertise in cardiology as well as decades of development together with users and customers. The company's headquarters are located in Danderyd, Stockholm. The company has, since 1998, a wholly owned subsidiary based in the United Kingdom and since 2022, a wholly owned subsidiary based in Denmark.

MobiMed is a modular platform that connects and enable real-time information sharing throughout the prehospital care chain. It is currently used by over 12,000 paramedics in over 2,700 emergency vehicles. The platform, MobiMed, consists of several product modules that are completely integrated but can also be used stand-alone. MobiMed comprises four main solutions: MobiMed Monitor, that measures, monitors and shares patients' vital parameters and ECG in real-time, MobiMed ePR, – an electronic patient record for decision support, collection of patient data and clinical documentation, MobiMed enRoute, – a tool for navigation and case management, and MobiMed Life – a range of stand-alone defibrillators.

MobiMed saves vital seconds and enable healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.
 
Read more about Ortivus at www.ortivus.com

This information is information that Ortivus is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-05-04 08:30 CEST.

Attachments

Ortivus Interim Report Jan Mar 2023

This entry was posted in . Bookmark the permalink.